Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
MWN-AI** Summary
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) recently reported its financial results for the full year ended December 31, 2025, highlighting significant advancements in its pipeline and a strategic rebranding aimed at reflecting its evolution as a leader in in vivo genome editing. The company completed a pre-IND meeting for its lead program, MGX-001, targeting Hemophilia A, with promising preclinical data showing curative FVIII activity in non-human primates (NHPs). This positions the company on track for a global IND submission expected in the fourth quarter of 2026, with clinical trials anticipated to begin in 2027.
As of December 31, 2025, Metagenomi reported cash, cash equivalents, and marketable securities totaling $160.8 million, which is expected to sustain operations through the fourth quarter of 2027. The company reported a reduction in R&D expenses to $94.4 million from $109.2 million in 2024, while G&A expenses also decreased to $26.8 million from $32.0 million the previous year.
In addition to MGX-001, Metagenomi announced encouraging progress in expanding its genetic editing platform, demonstrating proof-of-concept in treating secreted protein deficiencies and collaborating with Ionis Pharmaceuticals on new cardiometabolic targets. The rebranding to Metagenomi Therapeutics underscores a strengthened mission focused on developing curative genetic medicines.
Despite a net loss of $87.9 million for 2025, slightly increased from the previous year’s loss, the company's strategic moves and financial positioning signal a robust pathway forward. CEO Jian Irish emphasized the year as pivotal for refining their focus on high-potential therapeutic areas, which could enhance value creation as they advance toward pivotal clinical stages.
MWN-AI** Analysis
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) has reported substantial strides towards advancing its genome-editing technologies, particularly pivoting towards its lead candidate, MGX-001, for Hemophilia A. The company concluded its pre-IND meeting following promising preclinical outcomes demonstrating curative FVIII activity in non-human primates, positioning MGX-001 as a potential best-in-class therapy. The anticipated global regulatory submission, including an IND submission targeted for Q4 2026, indicates a robust pathway towards clinical trials in 2027, enhancing investor confidence in its long-term prospects.
Financially, Metagenomi reported $160.8 million in cash and equivalents as of December 31, 2025, providing operational runway through Q4 2027. This generous cash position, paired with a reduction in R&D expenses to $94.4 million from $109.2 million in 2024, suggests prudent fiscal management as the company refines its focus and optimizes costs. Furthermore, the decreased general and administrative expenses demonstrate ongoing efforts to streamline operations.
Investors should note the company’s recent rebranding as Metagenomi Therapeutics, which reflects a strategic evolution aimed at emphasizing its commitment to unlocking the potential of precision genetic medicine. The successful presentation of additional projects, such as collaborations targeting cardiometabolic diseases and advancements in treating secreted protein deficiencies, underlines the diverse potential of its proprietary technologies.
However, investors should remain cautious about the inherent risks associated with biotech investments, particularly those linked to the timing of regulatory approvals and the unpredictable nature of clinical trial outcomes. Assessing the competitive landscape is also essential as the field of gene editing rapidly evolves.
Overall, Metagenomi Therapeutics appears to be on solid footing as it enters 2026. The strong financial position, along with strategic advancements and a clear pipeline, suggests potential for growth; hence, it may be considered a viable investment for those with a tolerance for the inherent risks of the biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026
Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company’s strategic evolution
$160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027
EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the full year ended December 31, 2025, and provided business updates.
“2025 was a pivotal year for Metagenomi as we sharpened our strategic focus, advanced our core genome-editing technologies, and continued to demonstrate the breadth and durability of our technology across multiple therapeutic areas,” said Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company. “Over the year, we made meaningful progress across our pipeline and collaborations, which reinforce the versatility of our signature technologies and our ability to engineer differentiated genome-editing solutions tailored to specific disease contexts. With our corporate rebranding, we are entering 2026 with a clearer identity and mission centered on unlocking the full potential of precision genetic medicines.”
Fourth Quarter 2025 Updates
MGX-001 - Hemophilia A Program
- Announced preclinical data from MGX-001 hemophilia A program that demonstrated curative FVIII activity in NHPs for a therapy with best-in-class treatment potential supporting advancement into clinical development.
- Completed a pre-IND meeting for MGX-001 and remain on track for regulatory submission to advance global clinical program, including an IND in the fourth quarter of 2026, and subject to regulatory clearance, initiate clinical trials in 2027.
Secreted Protein Deficiencies
- Demonstrated in vivo proof-of-concept in NHPs for Antithrombin (AT-III) Deficiency evidencing the potential to expand the MGX-001 site-specific genome integration system into additional curative therapies for secreted protein disorders.
Cardiometabolic Indications
- Presented preclinical data supporting APOC3 as a new collaboration target with Ionis Pharmaceuticals (“Ionis”) at the Nature Conference, “Cracking the Code: Nucleic Acid Medicines Coming of Age.”
- APOC3 is a part of Wave 1 of the Ionis collaboration, which includes four targets in significant cardiometabolic indications.
- Completed corporate name change to Metagenomi Therapeutics, Inc. to reflect the Company’s strategic evolution focused on advancing its lead program in hemophilia A and other compelling programs and technologies that have the highest probability of success.
Full Year 2025 Financial Results
Cash Position: Cash, cash equivalents, and available-for-sale marketable securities were $160.8 million as of December 31, 2025.
R&D Expenses: Research and development (R&D) expenses were $94.4 million for the full year ended December 31, 2025, compared to $109.2 million for the full year ended December 31, 2024.
G&A Expenses: General and administrative (G&A) expenses were $26.8 million for the full year ended December 31, 2025, compared to $32.0 million for the full year ended December 31, 2024.
About Metagenomi Therapeutics
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with best-in-class treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. The Company is also currently pursuing other secreted protein deficiencies leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward??Looking Statements
This press release contains ?“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as ? “anticipate,” ? “believe,” ? “could,” “estimate,” ?“expect,” ?“goal,” ?“intend,” ?“look forward to,” ?“may,” ?“plan,” ?“potential,” ?“predict,” ?“project,” ?“should,” ?“will,” ?“would” and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies and make regulatory filings such as INDs, expectations regarding MGX-001 including the preclinical profile being potentially competitive with best-in-class treatment options and timing to submit the IND/CTA package, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in ?“Risk Factors,” in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contact:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
| Condensed Financial Statements Condensed Balance Sheet Data (Unaudited) | |||||||
| December 31, | December 31, | ||||||
| (in thousands) | 2025 | 2024 | |||||
| Cash, cash equivalents and available-for-sale marketable securities | $ | 160,799 | $ | 248,307 | |||
| Total assets | $ | 221,103 | $ | 324,599 | |||
| Total liabilities | $ | 62,507 | $ | 89,742 | |||
| Total stockholders’ equity | $ | 158,596 | $ | 234,857 | |||
| Total liabilities and stockholders’ equity | $ | 221,103 | $ | 324,599 | |||
| Condensed Statements of Operations (Unaudited) | |||||||
| Years Ended December 31, | |||||||
| (in thousands, except share and per share data) | 2025 | 2024 | |||||
| Collaboration revenue | $ | 25,210 | $ | 52,295 | |||
| Operating expenses: | |||||||
| Research and development | 94,433 | 109,179 | |||||
| General and administrative | 26,790 | 32,017 | |||||
| Total operating expenses | 121,223 | 141,196 | |||||
| Loss from operations | (96,013 | ) | (88,901 | ) | |||
| Other income (expense): | |||||||
| Interest income | 9,470 | 14,722 | |||||
| Change in fair value of long-term investments | (1,292 | ) | (9,185 | ) | |||
| Other expense, net | (91 | ) | (207 | ) | |||
| Total other income, net | 8,087 | 5,330 | |||||
| Net loss before benefit from income taxes | (87,926 | ) | (83,571 | ) | |||
| Benefit from income taxes | 58 | 5,513 | |||||
| Net loss | $ | (87,868 | ) | $ | (78,058 | ) | |
| Net loss per share attributable to common stockholders, basic and diluted | $ | (2.36 | ) | $ | (2.36 | ) | |
| Weighted average common shares outstanding, basic and diluted | 37,251,050 | 33,027,889 | |||||
FAQ**
What are the main insights gained from the pre-IND meeting regarding Metagenomi Inc. MGX's MGX-001 program, and how do they impact the anticipated IND submission timeline in 4Q 2026?
How does Metagenomi Inc. MGX plan to leverage its proprietary genome editing technologies to expand beyond the MGX-001 program, particularly concerning indications like Antithrombin Deficiency?
What strategies does Metagenomi Inc. MGX have in place to ensure sufficient cash runway extends through 4Q 2027 while managing R&D and G&A expenses effectively?
With the recent corporate name change to Metagenomi Therapeutics, Inc., how does Metagenomi Inc. MGX intend to communicate its strategic evolution and value proposition to potential investors and stakeholders?
**MWN-AI FAQ is based on asking OpenAI questions about Metagenomi Inc. (NASDAQ: MGX).
NASDAQ: MGX
MGX Trading
-8.09% G/L:
$1.489 Last:
326,987 Volume:
$1.55 Open:
